EXCIVA Trademark

Trademark Overview


On Thursday, October 6, 2016, a trademark application was filed for EXCIVA with the United States Patent and Trademark Office. The USPTO has given the EXCIVA trademark a serial number of 87195766. The federal status of this trademark filing is REGISTERED as of Tuesday, July 5, 2022. This trademark is owned by EXCIVA UG (haftungsbeschränkt). The EXCIVA trademark is filed in the Pharmaceutical Products category with the following description:

Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of inf...
exciva

General Information


Serial Number87195766
Word MarkEXCIVA
Filing DateThursday, October 6, 2016
Status700 - REGISTERED
Status DateTuesday, July 5, 2022
Registration Number6782565
Registration DateTuesday, July 5, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 19, 2017

Trademark Statements


Goods and ServicesMedical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the prevention of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, elixirs for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS), peripheral nerve disorders, and mental, neurological, psychological, psychosomatic, posttraumatic stress, alcohol, nicotine, and drug dependence related diseases, disorders and conditions; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations in the form of granules and liquids for controlling and removing moss; Preparations in the form of powders for controlling and removing moss; Preparations to destroy mildew; Preparations to prevent chewing or biting by animals; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 13, 2016
Primary Code005
First Use Anywhere DateMonday, July 2, 2018
First Use In Commerce DateMonday, July 2, 2018

Trademark Owner History


Party NameEXCIVA LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressVernon Hills, IL 60061

Party NameEXCIVA LLC
Party Type21 - New Owner After Publication
Legal Entity Type16 - Limited Liability Company
AddressVernon Hills, IL 60061

Party NameEXCIVA UG (haftungsbeschränkt)
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressVERNON HILLS, IL 60061

Party NameEXCIVA UG (haftungsbeschränkt)
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressHeidelberg 69118
DE

Trademark Events


Event DateEvent Description
Tuesday, July 5, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, July 5, 2022REGISTERED-PRINCIPAL REGISTER
Thursday, June 2, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, June 1, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, June 1, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 1, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, May 28, 2022ASSIGNED TO LIE
Wednesday, May 25, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, February 15, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, February 15, 2022FINAL REFUSAL E-MAILED
Tuesday, February 15, 2022SU - FINAL REFUSAL - WRITTEN
Friday, January 21, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 20, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 20, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 7, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, October 7, 2021NON-FINAL ACTION E-MAILED
Thursday, October 7, 2021SU - NON-FINAL ACTION - WRITTEN
Tuesday, September 14, 2021STATEMENT OF USE PROCESSING COMPLETE
Tuesday, August 31, 2021IU INFORMAL RESPONSE RECEIVED
Tuesday, August 31, 2021TEAS STATEMENT OF USE RECEIVED
Tuesday, August 31, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, August 31, 2021USE AFFIDAVIT FAILED FORMALITIES
Wednesday, August 25, 2021USE AMENDMENT FILED
Tuesday, August 31, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, August 28, 2021TEAS POST PUBLICATION AMENDMENT RECEIVED
Saturday, August 28, 2021ITU OFFICE ACTION ISSUED FOR STATEMENT OF USE
Saturday, August 28, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 25, 2021TEAS STATEMENT OF USE RECEIVED
Tuesday, May 11, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, March 29, 2021TTAB RELEASE CASE TO TRADEMARKS
Monday, March 29, 2021OPPOSITION TERMINATED NO. 999999
Monday, March 29, 2021BOARD DECISION COUNTERCLAIM DENIED
Monday, March 29, 2021ASSIGNED TO EXAMINER
Thursday, March 25, 2021OPPOSITION DISMISSED NO. 999999
Wednesday, July 29, 2020ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Sunday, July 5, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sunday, July 5, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sunday, July 5, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sunday, July 5, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Sunday, July 5, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 7, 2019ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Tuesday, April 3, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 17, 2018OPPOSITION INSTITUTED NO. 999999
Tuesday, October 17, 2017EXTENSION OF TIME TO OPPOSE RECEIVED
Wednesday, September 27, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 26, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 19, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 19, 2017PUBLISHED FOR OPPOSITION
Wednesday, August 30, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, August 12, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 24, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 24, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 18, 2017ASSIGNED TO LIE
Sunday, June 11, 2017TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, May 26, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, May 1, 2017NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, May 1, 2017FINAL REFUSAL E-MAILED
Monday, May 1, 2017FINAL REFUSAL WRITTEN
Thursday, April 27, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 27, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 27, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, January 14, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, January 14, 2017NON-FINAL ACTION E-MAILED
Saturday, January 14, 2017NON-FINAL ACTION WRITTEN
Friday, January 13, 2017ASSIGNED TO EXAMINER
Thursday, October 13, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, October 10, 2016NEW APPLICATION ENTERED IN TRAM